SCHEMBL25085593

SCHEMBL25085593

CCc1ccc2ccc(N(C)C)cc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.55
CYP2A6 P11509 1/20 0.55
TERT O14746 1/20 0.45
APP P05067 1/20 0.45
ALDH1A1 P00352 2/20 0.45
TSHR P16473 2/20 0.45
CYP3A4 P08684 1/20 0.45
MAPK1 P28482 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
PSMB5 P28074 2/20 0.45
SIGMAR1 Q99720 1/20 0.41
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
AKR1C3 P42330 1/20 0.38
AKR1C2 P52895 1/20 0.38
TRPA1 O75762 1/20 0.38
EGFR P00533 2/20 0.37
CALM1 P0DP23 1/20 0.37
NOS1 P29475 2/20 0.36
CRHR1 P34998 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13487155 0.94 CYP1A2 (0.57) CYP1A2CYP2A6TERTAPPALDH1A1
SCHEMBL29475635 0.82 CYP2A6 (0.76) CYP1A2CYP2A6ALDH1A1MAPK1SIGMAR1
SCHEMBL1878783 0.82 CYP2A6 (0.76) CYP1A2CYP2A6ALDH1A1MAPK1SIGMAR1
SCHEMBL12363750 0.82 CYP1A2 (0.53) CYP1A2CYP2A6TERTSIGMAR1AKR1C3
SCHEMBL15131776 0.78 SIGMAR1 (0.47) CYP1A2CYP2A6TERTAPPALDH1A1
SCHEMBL9066719 0.78 TERT (0.57) CYP1A2TERTAPPALDH1A1TSHR
SCHEMBL13432618 0.77 CYP1A2 (0.74) CYP1A2CYP2A6SIGMAR1AKR1C3AKR1C2
SCHEMBL14311184 0.76 APP (0.45) CYP2A6TERTAPPALDH1A1TSHR
SCHEMBL6044185 0.76 APP (0.49) CYP1A2CYP2A6TERTAPPALDH1A1
SCHEMBL12292317 0.75 CYP1A2 (0.50) CYP1A2CYP2A6APPALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230062022-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS NUVATION BIO INC (US) 2023-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230062022-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS CDK4, CDK6, CDK8 CYP1A2 3068/4885CYP2A6 1221/4885TERT 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.